Posts Tagged ‘science jobs uk’

£1bn funding boost for seven science and research projects

Thursday, November 1st, 2012

As reported by The Pharma Times, the UK Research Partnership Investment Fund has granted a £1bn cash boost to a further seven science and research projects. This brings the total number of projects receiving funding to 14.

The seven new science and research projects include:

University of Manchester, The Christie Hospital and Cancer Research UK

A £38 million partnership between the University of Manchester, The Christie Hospital and Cancer Research UK. This project will look into cancer treatments and will focus on five research areas: radiation therapy, lung cancer, women’s cancer, melanoma, haematological oncology. Plans for the new research centre have now been approved, find out more here.

 

£1bn funding boost for seven science and research projectsUCL and Great Ormond Street Hospital

An £85 million partnership with University College London and the Great Ormond Street Hospital. These organisations will be working together to find treatments and cures for rare diseases.

 

 

 

 

£1bn funding boost for seven science and research projectsQueens University Belfast, The Atlantic Philanthropies, The Sir Jules Thorn Charitable Trust and the Insight Trust for the Visually Impaired

Researchers will come together to work on vision sciences and new research programmes in diabetes and genomics. Click here to find out more about the new research centre.

 

 

 

£1bn funding boost for seven science and research projectsUniversity of Nottingham, GlaxoSmithKline and the Centre in Sustainable Chemistry

The aim of this project is to ensure that chemistry becomes more energy/resource efficient and sustainable when meeting the need for developing increasingly innovative medicine.

 

 

 

£1bn funding boost for seven science and research projectsSwansea University, British Petroleum and TATA Steep Europe

This research will focus on the development of existing energy processes as well as the safe deployment and integration of new green energy technologies.

 

 

 

 

£1bn funding boost for seven science and research projectsBrunel University and TWI

This will act as a dedicated national hub for interdisciplinary research into the soundness of the design and constructions of products, plant and infrastructure across the energy, transport and advanced manufacturing sectors.

 

 

 

 

£1bn funding boost for seven science and research projectsImperial College London and Voreda

These two organisations will collaborate in a £150million partnership to develop the Research and Translation Hub, which will provide high specification research and incubator space for 1,000 researchers investigating next generation materials and spin-out companies. Click here to find out more >

 

 

 

 

About the UK Research Partnership Investment Fund

The £100 million UK Research Partnership Investment Fund is designed to support investment in higher education research facilities. The fund was set up in 2012 and will run for three years until 2015. Click here to find out more >

Speaking of the science and research funding, David Willetts, minister for universities and science, said: “It is fantastic that our top businesses and top charities are queuing up to collaborate with our world-class universities. They want to work together to deliver innovation, commercialisation and growth, which will help make sure the UK competes and thrives in the global race.

 

 

Looking for a new job in science? Click here to search our science jobs online now >

A new-state-of-the-art Science park will bring 2,000 jobs to Wiltshire

Thursday, October 25th, 2012

ThA new-state-of-the-art Science park will bring 2,000 jobs to Wiltshiree Swindon Advertiser has reported that a new state-of-the-art science park will be developed at Porton in Wiltshire creating more than 2,000 jobs over a 10-year-period and bringing national and international investment into the area.

Wiltshire Council and a joint development company, comprising Trebor Developments LLP and Wrenbridge Land Limited, will develop the science park. The successfully bided  for £10m funding from the Department of Business, Innovation and Skills (BIS). This will help kick-start the first phase of the science park project, creating the infrastructure for the planned 355,000 sq ft science park and a new 23,000 sq ft innovation centre

This new science park will  provide facilities for science- and research-based industries and could attract £70m of private sector investment over the next 10 years.

 

Are you looking for a new science based role?

Click here to see our latest science jobs

Pharmaceutical Export Sales Manager – Home Working / London

Monday, October 22nd, 2012

Jason Johal at CK Science is currently recruiting for a Pharmaceutical Export Sales Manager for an amazing role with an MHRA licensed pharmaceutical manufacturing organisation based in London on a full time, permanent basis.

Responsibilities:

This newly formed Pharmaceutical Export Sales Manager role offers a blank canvas in regards to where you can take it and what you can achieve. It would be ideal for a person with an “explorer” personality and for someone looking for a role with autonomy, challenges and happy to travel globally.

The company are looking for someone that can grow their export business by developing strategies, using current/new contacts within Europe, the Middle East and by utilising their regulatory and pharmaceutical knowledge.

As an Export Sales Manager you will:

  • Develop the overall sales strategy plan for export sales
  • Plan and manage overseas sales through direct customers, distributors and other relevant sales outlets
  • Identify potential partners / distributors / countries for export opportunities
  • Manage export accounts to achieve sales targets, liaising closely with the Sales & Marketing Director, to develop and maximise all sales opportunities
  • Negotiate and manage contracts for sales/ distribution as required to enable effective trading, operations and customer relations
  • Develop knowledge and understanding of local requirements for pharmaceuticals, medical devices and “specials”.
  • Develop export programmes to promote new products and actively support all product promotions to customers
  • Liaise with customers services to process orders, enquiries, sample requests, catalogue requests and offer quotations
  • Deal with customer complaints in a professional and helpful manner
  • Organise and attend customer visits and represent company at trade shows as part of an agreed plan
  • Manage the movement of products in and out of the country in accordance with organisational policy and procedure, and to comply with relevant local, country and international law and process
  • Manage the necessary administration and documentation for the efficient, cost-effective and lawful execution of all export activities. Liaising with regulatory, finance and other departments as required

Qualifications:

The successful applicant for this Export Sales Manager will have the following qualifications, skills & experiences:

  • An experienced Pharmaceutical export sales professional
  • An understanding and experience of setting up distributors in overseas markets
  • Knowledge or experience of the ophthalmology (highly advantageous not essential)
  • The ability to travel for prolonged periods of time
  • A working knowledge of regulatory issues overseas
  • The ability to develop and execute coherent business strategies and plans
  • A detailed understanding of Pharmaceutical industry
  • Be self motivated (minimum supervision required)
  • Strong Communication skills (Verbal and Written)
  • A second European language would be an advantage but is not essential

Benefits:

This Pharmaceutical Export Sales Manager role is a really exciting job for a pharmaceutical sales professional as it offers the opportunity to establish and then develop your own strategies and the freedom to build your career in the direction you want to go.  If successful, you will be joining a Specials Manufacturer with a growing portfolio of branded licensed products coupled with a world renowned reputation. In return there is an attractive salary, coupled with excellent benefits and travel opportunities.

Jason Johal - Pharmaceutical Recruitment

Please contact Jason for more details.

How to apply:

Apply online:

To apply for this Export Sales Manager position, contact Jason Johal via email: jjohal@ckscience.co.uk or 01438 723 500. Please quote reference ST25513 in all correspondence.

 

Are you looking for a new job in the pharmaceutical  industry?

Click here to see our latest pharmaceutical jobs?

Pharmaceutical Export Sales Manager

 

 

 

 

GSK invest 10 million euros at their facility in Sligo, Ireland

Thursday, October 18th, 2012

Pharmatimes have reported that GlaxoSmithKline has decided to keep open its facility in Sligo Ireland and will instead invest 10 million euros into the plant.

GSK acquired the facility in Sligo when GSK bought the dermatology specialist Stiefel Laboratories for up to $3.6 billion in 2009.

There will be some jobs cuts at the plant over the next two years, which currently employs 180 people, with a “gradual” reduction to 120. However, GlaxoSmthKline estimated there would be an additional 50 jobs added in 2014 as the plant improved skills and capacity.

 

If you are looking for a new job in science why not look at our current science based vacancies?

Click here to see our latest jobs in the science industry

UK stem cell pioneer shares Nobel Prize in Medicine

Monday, October 8th, 2012

The BBC has reported that two pioneers of stem cell research have shared the Nobel prize for medicine and/ or physiology

John Gurdon from the UK and Shinya Yamanaka from Japan have been jointly awarded the prize for their work in transforming specialised cells into stem cells, which can become any other type of cell in the body. It is hoped the techniques discovered will revolutionise medicine by using a sample of a person’s skin to create stem cells.

Prof Anthony Hollander, the head of cellular and molecular medicine at the University of Bristol, said: “This joint Nobel Prize traces and celebrates the wonderful scientific journey from John Gurdon’s pioneering early work to the sensational discovery of somatic cell reprogramming by Shinya Yamanaka. It’s fantastic news for stem cell research.”

The prize was awarded this morning at the Karolinska Institute in Sweden, and is the most coveted award in medical science. The Nobel committee said these winners  had “revolutionised” science

 

If you are looking for a new job in science why not look at our current science based vacancies?

Click here to see our latest jobs in the science industry

 

Allergans Botox receives UK approval for treatment of MS/spinal injury

Tuesday, October 2nd, 2012

CK Science - Scientific Recruitment AgencyPharmaTimes have reported that Allergan’s Botox is now licensed in the UK for patients who have continence issues because of multiple sclerosis or a spinal injury.

The Medicines and Healthcare products Regulatory Agency has give Allergan permission to use Botox (botulinum toxin type A) for managing urinary incontinence caused by neurogenic detrusor overactivity due to subcervical spinal cord injury or multiple sclerosis (MS),

Professor Christopher Chapple, Urology Department, Royal Hallamshire Hospital, Sheffield NHS Trust and a key investigator in the neurogenic detrusor overactivity registration trials, has welcomed the new license, noting that “being able to better control and manage bladder function can be life-changing for patients”.

 

If you are looking for a new job in science why not look at our current science based vacancies?

Click here to see our latest jobs in the science industry

UCB launches its new biotechnology facility in Belgium

Tuesday, September 18th, 2012

PharmaTimes has reported that UCB has launched its 65 million euro pilot biotechnology plant in Belgium.

The new facility is located at its Braine-l’Alleud site and will employ 100 employees. This new facility will produce cell culture-based therapeutic proteins that are dedicated to accelerating the availability of new drugs for severe diseases with a focus on the research and clinical trial phases

This new facility is designed enable UCB to improve its biological medicines.

Chief executive Roch Doliveux said that “today, 33% of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB’s current R&D pipeline”. He added that “with this bio pilot plant, we will more rapidly initiate clinical studies of new antibody-based therapeutics”.

 

Are you looking for a new science based role?

Click here to see our latest science jobs

Novartis’s rare cancer drug is launched in the UK

Tuesday, September 11th, 2012

Pharmatimes have reported that Novartis have launched their new drug Jakavi which means for the first time patients in the UK with a rare form of blood cancer will now have access to this targeted therapy

Jakavi (ruxolitinib) is a first-in-class JAK 1 and JAK 2 inhibitor, and is now available to treat patients in the UK with disease-related enlarged spleen or various forms of myelofibrosis, which affects around 0.34-0.76 people in every 100,000.

Myelofibrosis is a rare, potentially life-threatening blood cancer characterised by bone marrow failure, enlarged spleen and debilitating symptoms including extreme fatigue, poor quality of life and weight loss, and shortened survival.

Jakavi received EU approval at the end of August 2012

 

Are you looking for a new job in the pharmaceutical  industry?

Click here to see our latest pharmaceutical jobs?

CK Science are exhibiting at Pharmsci 2012 Conference

Thursday, September 6th, 2012

CK Science is proud to announce that we will be exhibiting at Pharmsci 2012 Conference from the 12th of September to the 14th of September 2012 on stand number 30.

 

About Pharma Sci 2012 conference:

Pharmsci 2012 Conference is the premier Pharmaceutical Sciences Conference in the UK organised by the Academy of Pharmaceutical Sciences (APS) taking place at the East Midlands Conference Centre. This year’s conference will showcase the best of pharmaceutical science from the UK and around the world bringing together academic and industrial institutions, providing state of the art technologies and a platform for the development of new pharmaceutical talent.

There will also be presentations on new findings from prestigious leaders and young science researchers on various topics including Polymeric and self-assembled delivery systems, The future of in-vitro drug release testing approaches in product development, Bugs and drugs with a focus on anti-infectives, Tackling counterfeiting by formulation and processing approaches, ‘Green’ formulations and processes, Medicinal chemistry, Biopharmaceutics, Paediatric drug delivery and Inhaled product development. 

APS are keen to attract both undergraduate and postgraduate students by offering a programme that develops presentation skills and the scientific networks essential for future careers. There will also be opportunities to network and enhance knowledge for both academic and industrial attendees in a wide range of disciplines. 

 

Visit CK Science on stand number 30

So, if you are looking for a new position in the science industry, or are looking to expand your team, please come along to stand 30 to say hello.

We will be happy to help and give advice on finding a new job in the science industry. Or if you would like to add to your current team we will be pleased to talk to with you too.

 

Prize Draw:

 You could even be in with a chance of winning a bottle of champagne by entering your business card into our prize draw!

 

If you are looking for a new job in science why not look at our current science based vacancies?

Click here to see our latest jobs in the science industry

              

£2.8 billion renewable energy investment in Scotland

Thursday, August 16th, 2012

Scottish Development International has reported that Scotland’s renewable energy industry has attracted £2.8 billion capital investment since 2009.

Onshore wind accounts for 57 percent of total investment with 21 percent going to offshore wind. The rest of the investment has been deivded between wave and tidal energy, solar photovoltaic, hydro energy, landfill gas and biofuels.

Niall Stuart, chief executive of Scottish Renewables said “These figures show Scotland’s renewables industry is very much bucking the economic trend.  During the downturn our industry has delivered some £2.8bn of much needed capital investment in our economy.  This has helped to grow the supply chain, secure the future of many companies and support more than 11,000 jobs”

 

Are you looking for a new science based role?

Click here to see our latest science jobs

Search for a job

Advanced search

20 years Download the CK Science iPhone App

Subscribe to our newsletter

Preview
Powered by FeedBlitz


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close